Could stem cells slow ALS? new trial results are in

NCT ID NCT04745299

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This Phase 3 trial tested a stem cell treatment called Lenzumestrocel in 123 people with ALS. The treatment uses the patient's own bone marrow stem cells and is given alongside the standard drug Riluzole. The goal was to see if it could slow the disease and improve survival and function. Results are being analyzed to determine if this approach offers real benefits.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Lenzumestrocel (stem cells from the patient's own bone marrow)
What this could lead to
If it works, this could slow the progression of ALS and help patients maintain function longer.
What could go wrong
This is a single Phase 3 trial with 123 participants. Results may not apply to everyone, and stem cell treatments carry risks like infection or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hanyang university hospital

    Seoul, Seoul, 04763, South Korea

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, Kyungsangnam-do, 50612, South Korea

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.